BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 27027301)

  • 1. The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin.
    Ponziani FR; Scaldaferri F; Petito V; Paroni Sterbini F; Pecere S; Lopetuso LR; Palladini A; Gerardi V; Masucci L; Pompili M; Cammarota G; Sanguinetti M; Gasbarrini A
    Dig Dis; 2016; 34(3):269-78. PubMed ID: 27027301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation.
    Ponziani FR; Zocco MA; D'Aversa F; Pompili M; Gasbarrini A
    World J Gastroenterol; 2017 Jul; 23(25):4491-4499. PubMed ID: 28740337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease.
    Lopetuso LR; Napoli M; Rizzatti G; Gasbarrini A
    Expert Opin Investig Drugs; 2018 Jun; 27(6):543-551. PubMed ID: 29865875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
    Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
    World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: the antimicrobial effects of rifaximin on the gut microbiota.
    DuPont HL
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():3-10. PubMed ID: 26618921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin.
    Lopetuso LR; Petito V; Scaldaferri F; Gasbarrini A
    Mini Rev Med Chem; 2015; 16(3):179-85. PubMed ID: 26643042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
    Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
    Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
    DuPont HL
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
    Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
    Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.
    Jin Y; Ren X; Li G; Li Y; Zhang L; Wang H; Qian W; Hou X
    J Gastroenterol Hepatol; 2018 Feb; 33(2):443-452. PubMed ID: 28573746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
    Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
    Harris LA; Baffy N
    Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.
    Laterza L; Ianiro G; Scoleri I; Landi R; Bruno G; Scaldaferri F; Gaetani E; Campanale M; Gasbarrini A
    Expert Opin Pharmacother; 2015 Mar; 16(4):607-15. PubMed ID: 25641072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin: beyond the traditional antibiotic activity.
    Calanni F; Renzulli C; Barbanti M; Viscomi GC
    J Antibiot (Tokyo); 2014 Sep; 67(9):667-70. PubMed ID: 25095806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
    Pimentel M
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
    Bajaj JS
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifaximin: An Antibiotic with Important Biologic Effects.
    DuPont HL
    Mini Rev Med Chem; 2015; 16(3):200-5. PubMed ID: 26202192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial.
    Madsen BS; Trebicka J; Thiele M; Israelsen M; Arumugan M; Havelund T; Krag A
    Trials; 2018 Feb; 19(1):143. PubMed ID: 29482588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of antibiotics for treatment of inflammatory bowel disease.
    Nitzan O; Elias M; Peretz A; Saliba W
    World J Gastroenterol; 2016 Jan; 22(3):1078-87. PubMed ID: 26811648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation.
    Weber D; Oefner PJ; Dettmer K; Hiergeist A; Koestler J; Gessner A; Weber M; Stämmler F; Hahn J; Wolff D; Herr W; Holler E
    Bone Marrow Transplant; 2016 Aug; 51(8):1087-92. PubMed ID: 26999466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.